title: Cerebrospinal fluid cortisol and progesterone profiles and outcomes prognostication after severe traumatic brain injury.
abstract: Despite significant advances in the management of head trauma, there remains a lack of pharmacological treatment options for traumatic brain injury (TBI). While progesterone clinical trials have shown promise, corticosteroid trials have failed. The purpose of this study was to (1) characterize endogenous cerebrospinal fluid (CSF) progesterone and cortisol levels after TBI, (2) determine relationships between CSF and serum profiles, and (3) assess the utility of these hormones as predictors of long-term outcomes. We evaluated 130 adults with severe TBI. Serum samples (n=538) and CSF samples (n=746) were collected for 6 days post-injury, analyzed for cortisol and progesterone, and compared with healthy controls (n=13). Hormone data were linked with clinical data, including Glasgow Outcome Scale (GOS) scores at 6 and 12 months. Group based trajectory (TRAJ) analysis was used to develop temporal hormone profiles delineating distinct subpopulations. Compared with controls, CSF cortisol levels were significantly and persistently elevated during the first week after TBI, and high CSF cortisol levels were associated with poor outcome. As a precursor to cortisol, progesterone mediated these effects. Serum and CSF levels for both cortisol and progesterone were strongly correlated after TBI relative to controls, possibly because of blood-brain barrier disruption. Also, differentially impaired hormone transport and metabolism mechanisms after TBI, potential de novo synthesis of steroids within the brain, and the complex interplay of cortisol and pro-inflammatory cytokines may explain these acute hormone profiles and, when taken together, may help shed light on why corticosteroid trials have previously failed and why progesterone treatment after TBI may be beneficial.
authors.affiliation: 1 University of Pittsburgh , School of Medicine, Pittsburgh, Pennsylvania.
authors.forename: Martina
authors.initials: M
authors.lastname: Santarsieri
authors.forename: Christian
authors.initials: C
authors.lastname: Niyonkuru
authors.forename: Emily H
authors.initials: EH
authors.lastname: McCullough
authors.forename: Julie A
authors.initials: JA
authors.lastname: Dobos
authors.forename: C Edward
authors.initials: CE
authors.lastname: Dixon
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Berga
authors.forename: Amy K
authors.initials: AK
authors.lastname: Wagner
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid*; D001930:Brain Injuries / Q000097:blood / Q000134:cerebrospinal fluid*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015600:Glasgow Coma Scale; D023261:Glasgow Outcome Scale; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000134:cerebrospinal fluid*; D008297:Male; D008875:Middle Aged; D011374:Progesterone / Q000097:blood / Q000134:cerebrospinal fluid*; D011379:Prognosis; D011863:Radioimmunoassay; D020127:Recovery of Function / Q000502:physiology; D055815:Young Adult
chemical_list: D015415:Biomarkers; D011374:Progesterone; D006854:Hydrocortisone